Download Library
Date | Title | Documents |
---|---|---|
Anthera Corporate Presentation |
|
|
Additional Definitive Proxy Materials |
|
|
Form 10-K |
|
|
EULAR 2015 Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient-Reported Outcomes and Disease Activity in Patients with SLE |
||
Proxy Statement |
|
|
Definitive Additional Proxy Materials |
|
|
Effects of Blisibimod on Patient Reported Outcomes in Patients with SLE - ACR 2014 |
||
Anthera Corporate Update |
|
|
Effects Of Blisibimod On Serum Immunoglobulins and Infection Risk - 2013 ACR Presentation |
||
Effects of Chronic Treatment with Sub-cutaneous Blisibimod on Renal and Inflammation Biomarkers - PANLAR 2014 |
Displaying 1 - 10 of 24 results